Introduction
Lipid lowering therapy has been shown to reduce the rate of progression and even cause the regression of atherosclerotic lesions in coronary, 1 carotid 2 and peripheral arteries. 3 Moreover, recent work has confirmed that such therapy results in improved survival not only in patients with established coronary heart disease, 4 but also in asymptomatic men with mild or moderate hypercholesterolaemia. 5 We describe a case in which agressive lipid lowering therapy with an HMG CoA reductase inhibitor was associated with the regression of an atherosclerotic plaque of the renal artery.
Case
A 40-year-old man with intermittent claudication was referred 3 years ago with incidental bilateral renal artery stenosis demonstrated on digital subtraction renal angiography which was performed routinely at the end of peripheral arterial imaging. He had a history of treated hypertension and was a heavy smoker of 40 cigarettes per day. Both parents had treated hypertension but no history of premature vascular disease. His blood pressure was 122/83 mm Hg on amlodipine 10 mg and lisinopril 20 mg daily. Physical examination revealed warm and well perfused feet but absent pulses below the popliteal arteries. His total fasting cholesterol was 4.9 mmol/l, blood glucose 3.4 mmol/l, urea 7. In addition, there were bilateral atherosclerotic lesions in the proximal superficial femoral arteries, the left common and external iliac arteries. The patient declined percutaneous balloon angioplasty to the renal and peripheral vessels. He was advised to stop smoking, reduce his fat intake and was commenced on aspirin 150 mg daily. Furthermore, he was started on aggressive lipid lowering therapy with atorvastatin, with the aim of achieving a total fasting cholesterol level of 3.0 mmol/l. He was reviewed regularly and 3 years later a repeat angiogram was performed. At this time, he was still smoking but remained free from symptoms of claudication. His blood pressure was 120/86 mm Hg on lisinopril 10 mg; and his cholesterol 3.1 mmol/l on atorvastatin 20 mg daily. Serum creatinine remained stable at 111 mol/l. The repeat arteriogram was not entirely comparable with the initial one in terms of projection. However, despite this, it did show a suggestion of radiological improvement in the atheromatous plaque of the right renal artery (Figures 3 and 4; labelled a) . No improvement was seen in left renal artery and the possibility of underlying fibromuscular dysplasia was raised. Interestingly, improvement of atherosclerotic lesions in the peripheral arteries-particularly in the left iliac vessels, was also noted ( Figure 3 and Figure 4 ; labelled b,c). The patient again declined balloon angioplasty and medical therapy was continued.
Discussion
Atherosclerotic renal artery stenosis is a progressive condition and associated with hypertension, deterioration of renal function and considerable cardiovascular mortality. In patients with normal or less than 60% stenosis of the renal artery, the 3-year cumulative incidence of progression to over 60% stenosis and occlusion is approximately 50-60% and 5-7% respectively. 6, 7 The advancement of such stenotic lesions in renal arteries occurs despite the use of antihypertensive medication and is increasingly recognised as an important cause of end-stage renal failure. 8 Recently, restoration of vessel patency by balloon angioplasty has been shown to reduce the need for antihypertensive medication 9 and also to delay the progression of renal failure. 10 However, survival in patients with atherosclerotic renal artery stenosis is predominantly limited by cardiovascular disease, 11, 12 even in those treated with percutaneous renal angioplasty. 9, 13 It is already clear that treatment with statins significantly improves survival in patients both with and without established coronary heart disease. 4, 5 This case demonstrates that aggressive lowering of cholesterol with an HMG CoA reductase inhibitor beyond conventional levels may also lead to restoration of vessel patency in atherosclerotic renal artery stenosis through regression of the stenotic plaque. Furthermore, there was significant improvement in the atherosclerotic lesions in the left common iliac artery which was asociated with improvement in symptoms, despite continuation of smoking.
We are aware of one previous case report of similar regression using a fibrate and cholestyramine, 14 but to our knowledge this is the first case suggesting the regression of renal atherosclerosis with a statin. Therefore, aggressive treatment with a statin should, in our view, be considered mandatory in patients with atheromatous renovascular disease: first, as it is likely to improve survival by reducing the major cause of death in these patients-myocardial infarction and stroke; 9,11-13 and secondly, if our results are confirmed, treatment with a statin-if instituted early enough, may obviate the need for percutaneous balloon renal angioplasty and stenting.
